All In Biotech

Drug Trial Radar · NCT06866405

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Apr 16, 2025

Primary completion

Feb 24, 2028

Study completion Feb 24, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.

Conditions

  • RSV Infection

Interventions

  • RSVpreFBiological

    Single Dose

  • PlaceboBiological

    Single Dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of pregnant participants reporting local reactionsTime frame: From Day 1 Through at least Day 7 after Vaccination
  2. Percentage of pregnant participants reporting systemic eventsTime frame: From Day 1 Through at least Day 7 after Vaccination
  3. Percentage of pregnant participants reporting adverse eventsTime frame: From Day 1 through 4 weeks after vaccination
  4. Percentage of pregnant participants reporting serious adverse eventsTime frame: From Day 1 throughout the study
  5. In infant participants born to pregnant participants receiving a second dose of the study intervention, the percentage of participants reporting adverse events.Time frame: From birth through 1 month of age
  6. In infant participants born to pregnant participants receiving a second dose of the study intervention, the percentage of participants reporting serious adverse events and newly diagnosed medical conditions.Time frame: From birth through 6 months of age.
  7. Proportion of participants achieving neutralizing antibody to RSV A and RSV B at birthTime frame: At birth

Locations

99 sites in 4 countries. Site status is shown where the registry gives one.

  • Center for Research in Women's Health

    Birmingham, Alabama · Recruiting

  • Children's of Alabama

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham - School of Medicine

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham Women & Infants Center

    Birmingham, Alabama · Recruiting

  • USA Health Children's and Women's Hospital

    Mobile, Alabama · Recruiting

  • USA Health Strada Patient Care Center

    Mobile, Alabama · Recruiting

  • ClinMed, LLC

    Phoenix, Arizona · Recruiting

  • Valleywise Comprehensive Health Center Women's Clinic

    Phoenix, Arizona · Recruiting

  • Valleywise Health Medical Center

    Phoenix, Arizona · Recruiting

  • Ronald Reagan UCLA Medical Center (inpatient hospital)

    Los Angeles, California · Recruiting

  • Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug

    Los Angeles, California · Recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • UCLA (outpatient clinic)

    Los Angeles, California · Recruiting

  • UCLA Clinical and Translational Research Center (research clinic)

    Los Angeles, California · Recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • Lucile Packard Children's Hospital-Labor and Delivery Unit

    Palo Alto, California · Recruiting

  • Stanford Obstetrics Clinic

    Palo Alto, California · Recruiting

  • Stanford University Medical Center

    Palo Alto, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • Anschutz Health Sciences Building (AHSB)

    Aurora, Colorado · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • CU Research Pharmacy

    Aurora, Colorado · Recruiting

  • University of Colorado AO1 UCH

    Aurora, Colorado · Recruiting

  • University of Colorado Hospital Inpatient Pavilion

    Aurora, Colorado · Recruiting

  • University of Colorado Hospital Outpatient Pavilion

    Aurora, Colorado · Recruiting

  • University of Colorado Research II Building

    Aurora, Colorado · Recruiting

  • Citadelle Clinical Research

    North Miami Beach, Florida · Recruiting

  • Emerald Coast OBGYN Clinical Research

    Panama City, Florida · Recruiting

  • Emerald Coast Pediatrics

    Panama City, Florida · Recruiting

  • HCA Florida Gulf Coast Hospital

    Panama City, Florida · Recruiting

  • Advanced Specialty Research

    Boise, Idaho · Recruiting

  • Saint Alphonsus Regional Medical Center

    Boise, Idaho · Recruiting

  • St. Luke's Boise Medical Center

    Boise, Idaho · Recruiting

  • Clinical Research Prime

    Idaho Falls, Idaho · Recruiting

  • Saint Alphonsus Medical Center

    Nampa, Idaho · Recruiting

  • St. Luke's Nampa Medical Center

    Nampa, Idaho · Recruiting

  • Accellacare - McFarland

    Ames, Iowa · Recruiting

  • Mary Greeley Medical Center

    Ames, Iowa · Recruiting

  • McFarland Clinic, PC

    Ames, Iowa · Recruiting

  • The University of Kansas Hospital Investigational Drug Services

    Kansas City, Kansas · Recruiting

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.